Abstract:Objective To prepare a novel bone tissue engineering material with angiogenesis activity, and evaluate the biocompatibility and safety of the composites. Methods Endothelial progenitor cells (EPCs) were cotransfected with VEGF165 and ANG1 genes and loaded into porous bioactive glass-ceramic to make the composite. The expressions of VEGF165 and ANG1 in EPCs were detected by RT-PCR and Western blot. MTT cytotoxicity test, bone implantation test and electron microscopic examination were used to comprehensively evaluate the biocompatibility of the composite. Immunohistochemical staining of CD31 was used to analyze revascularization of the composite zones. Results Both RT-PCR and Western blot showed cotransfected EPCs expressed increased VEGF165 and ANG1. The results of MTT cytotoxicity test and bone implantation test showed that the material was non-toxic. Scanning electron microscope displayed many EPCs adhered to the surface of the material, and had a lot of pseudopods. HE staining revealed tissue surrounding the material grew well without marked inflammatory cell infiltration. CD31 immunohistochemical staining indicated newly-formed capillaries into the material, demonstrating that the new tissue engineering material has good biocompatibility. Conclusions The composite of porous bioactive glass-ceramic loaded with VEGF165 and ANG1 gene cotransfected EPCs has good biocompatibility, and can improve angiogenesis.